The Chinese medical team’s Revolutionary CAR-T Therapy: Long-lasting asthma relief with a single injection

### 🚀 The Chinese medical team’s Revolutionary CAR-T Therapy: Long-lasting asthma relief with a single injection.!

asthma

📢 Exciting news from the world of medical science! The team led by Professor Peng Min at Tsinghua University has made a groundbreaking advancement in CAR-T cell therapy. Imagine a world where chronic diseases like allergic asthma can be managed with just a single injection. This could soon be a reality!

🌬 **Asthma: A Global Challenge**

Asthma is one of the most common respiratory diseases, affecting over 300 million people worldwide and causing approximately 250,000 deaths annually. Despite the availability of treatments, many patients require lifelong medication, which can be costly and burdensome.

💡 **The Breakthrough Study**

On May 27, 2024, the team published their findings in *Nature Immunology*. Their paper, titled *A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice*, introduces a novel CAR-T cell named 5TIF4. This engineered cell targets the factors that trigger allergic reactions. Remarkably, just one injection of 5TIF4 cells was enough to suppress signs and symptoms of allergic asthma in mice for an extended period.

🧬 **How Does It Work?**

Traditional therapies for chronic diseases often require repeated or lifelong administration. However, the 5TIF4 cells are designed to be long-lived and multifunctional. They can neutralize eosinophils (cells involved in allergic reactions) and block key pathways (IL-4 and IL-13 signaling) that drive asthma. This innovative approach not only targets the symptoms but also addresses the underlying causes of the disease.

🚧 **Challenges and Solutions**

While CAR-T therapy has revolutionized cancer treatment, applying it to non-cancerous diseases presents unique challenges:

1. **Targeting Non-Cancer Tissues**: Unlike tumors, affected organs like lungs in chronic diseases cannot be eliminated.

2. **Longevity of Therapy**: Chronic diseases are lifelong, necessitating long-lasting therapeutic cells.

3. **Safety**: Current CAR-T treatments often involve invasive procedures like chemotherapy, which are not suitable for chronic conditions.

Peng Min’s team overcame these hurdles by engineering CAR-T cells that do not require pre-treatment and can persist in the body, providing continuous protection against asthma.

💭 **Future Prospects**

The implications of this research are profound. If these results can be replicated in humans, we might see a new era where a single injection offers long-term relief from asthma. Moreover, the same principles could potentially be adapted to treat other diseases involving eosinophils and type 2 cytokines, such as allergies, atopic dermatitis, and eosinophilic esophagitis.

📰 *Nature Immunology* also highlighted this study in an article titled *CAR T cells put the brakes on asthma*, emphasizing the expanding scope of CAR-T therapy beyond cancer treatment.

🌟 **Conclusion**

This pioneering research by Tsinghua University marks a significant milestone in the fight against chronic diseases. With further clinical trials, we could be on the brink of a revolution in how we treat asthma and possibly other chronic conditions. Stay tuned for more updates on this exciting journey towards better health and wellness!

📸 Don’t forget to follow for more groundbreaking health news and updates!

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#MedicalBreakthrough #CARTCellTherapy #AsthmaRelief #TsinghuaUniversity #HealthRevolution

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

10 months ago CAR-T

Miracle Unfolds: Zhejiang University Hospital’s Custom CRISPR/Cas9 Gene Editing + CAR-T Cell Therapy Rebirths Patients

🌟 Miracle Unfolds: Zhejiang University Hospital’s Custom CRISPR/Cas9 Gene Editing + CAR-T Cell Therapy Rebirths Patients 🌟

 

👨‍👧‍👦 (“I want to live to see my child go to university!”)👨‍👧‍👦

CAR-T Cell Therapy Patient

 

🎓 This heartfelt cry came from Mr. Sun, a 40-year-old patient from Guangzhou, who faced the formidable challenge of diffuse large B-cell lymphoma, a common adult lymphoma type.

 

🔬14 rounds of chemotherapy, 20 rounds of radiotherapy, total gastrectomy… For two years,

Mr. Sun sought treatment nationwide, endured endless suffering, yet couldn’t defeat the chameleon of the tumor world – diffuse large B-cell lymphoma.

“It’s tough. Prepare yourself mentally.” “I want to live to see my child go to university.”

 

🍋Seeking a glimmer of hope, he turned to Zhejiang University Hospital in Hangzhou. This time, the doctors said, “Let’s give it a try together.”

Multiple abdominal lymphoma lesions invading the intestinal wall, multiple rounds of chemo couldn’t stop the lymphoma from spreading everywhere. Intestinal wall invasion by lymphoma is a relative contraindication for CAR-T therapy, as it can lead to intestinal perforation, so he was no longer suitable for traditional CAR-T cell therapy.

 

🌿Prof. Liu Mingyao’s team and Prof. Huang He’s team used the Nobel Prize-winning CRISPR/Cas9 gene editing technology to precisely knock out the PD1 site in T lymphocytes and insert the targeted CD19 CAR molecule for tumor cells, creating a brand-new non-viral targeted integrated CAR-T cell (PD1-19bbz), and successfully completed Phase I clinical trials in humans for the first time, verifying the safety and efficacy of the new CAR-T cells.

 

💪The brand-new PD1-19bbz CAR-T cells, with a low risk of cytokine storms and other complications, gave Mr. Sun a new lease on life.

 

👑Mr. Sun received PD1-19bbz CAR-T cell infusion and returned. Fourteen days after CAR-T cell return, all indicators were normal. After evaluation, he was discharged. One month after the return, PET-CT evaluation showed that the large mass of tumor invading the intestinal mucosa in the original abdominal cavity had completely disappeared.

 

🏸Today, Mr. Sun has been disease-free for over 2 years.

In a recent follow-up, all of Sun’s examination results were normal, his weight had increased significantly compared to before his illness, and his complexion looked much healthier. “After cell therapy, my body suddenly felt normal again. My friends and family all say I’ve miraculously recovered. Now in my spare time, I even play badminton, completely restoring my pre-illness lifestyle.”

 

Tsinghua University

🎨Two years later, in the summer of 2022, Mr. Sun shared good news with the medical staff in Hangzhou: his child has been accepted to the School of Arts at Tsinghua University!

 

🎉To assess whether the condition is suitable for CAR-T therapy, you can submit Advanced Medicine in China for preliminary evaluation!

 

Email: doctor.huang@globecancer.com,

WhatsApp: +8613717959070

 

🌿 #MiracleRebirth #CRISPR #CARTCellTherapy #ZhejiangUniversity #TsinghuaUniversity #MedicalBreakthroughs #CancerTreatment